ArticleCellular & molecular biology letters2019
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Article in Cellular & molecular biology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Effects of apigenin on the proliferation, migration, and apoptosis of human diffuse large B-cell lymphoma OCI-LY3 cells.Discover oncology · 2025Article
- Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.Annals of hematology · 2024Review
- Profiling of microRNAs by next-generation sequencing: Potential biomarkers for diffuse large B-cell lymphoma.Journal of Taibah University Medical Sciences · 2024Article
- Epigenetic alterations and advancement of lymphoma treatment.Annals of hematology · 2024Review
- MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.Cancer cell international · 2024Review
- The expression mechanism of programmed cell death 1 ligand 1 and its role in immunomodulatory ability of mesenchymal stem cells.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2024Review
- KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway.Cellular & molecular biology letters · 2023Article
- Tumor immune checkpoints and their associated inhibitors.Journal of Zhejiang University. Science. B · 2022Review
- The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer.International journal of molecular sciences · 2022Review
- Review
- Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.Nature reviews. Clinical oncology · 2022Review
- The emerging role non-coding RNAs in B cell-related disorders.Cancer cell international · 2022Review
- MicroRNA-148a-3p suppresses cell proliferation and migration of esophageal carcinoma by targeting CEP55.Cellular & molecular biology letters · 2021Article
- miRNA-425-5p enhances diffuse large B cell lymphoma growth by targeting PTEN.Translational cancer research · 2021Article
- Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.Diagnostics (Basel, Switzerland) · 2021Review
- Review
- Exosomal circEIF3K from cancer-associated fibroblast promotes colorectal cancer (CRC) progression via miR-214/PD-L1 axis.BMC cancer · 2021Article
- Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.Journal of experimental & clinical cancer research : CR · 2021Review
- Review
- Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.BMC anesthesiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe explored the role and mechanism of miR-214 involvement in the progression of diffuse large B-cell lymphoma (DLBCL).
methodsThe expression levels of miR-214 and PD-L1 in human DLBCL cell lines and in tissue samples from patients with DLBCL were determined using quantitative RT-PCR. The dual-luciferase reporter assay was employed to determine the correlation between the expressions of miR-214 and PD-L1. Cell viability, invasiveness and apoptosis were respectively examined in cells of the DLBCL line OCI-Ly3 using CCK-8, transwell and flow cytometry assays. The expression level of PD-L1 was determined via immunoblotting. Inflammatory cytokine secretion was determined via enzyme-linked immune sorbent assay (ELISA).
resultsmiR-214 was downregulated and PD-L1 was upregulated in DLBCL tissues and cell lines in comparison to normal adjacent tissues or normal B-cell. This indicates a negative correlation in the expression levels. Overexpression of miR-214 inhibited cell viability and invasion and induced apoptosis of OCI-Ly3 cells. Moreover, miR-214 was shown to target PD-L1 mRNA by binding to its 3'-untranslated region (UTR). Knockdown of PD-L1 attenuated the malignant phenotype of OCI-Ly3 cells. Overexpression of miR-214 inhibited tumor growth by targeting PD-L1 in vivo.
conclusionBy targeting PD-L1, miR-214 regulates the progression of DLBCL in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.